TruLeaf Medical Expands First-in-Human Clinical Program: Successfully Implants Breakthrough RoseDoc™ Platform via Pure Percutaneous Access
AllMeD Solutions subsidiary demonstrates procedural success in Uzbekistan, building on positive 1-year follow-up data from its initial first-in-human cohort. OR AKIVA, Israel, Oct. 22, 2026 /PRNewswire/ -- AllMeD Solutions, Inc. (TASE: ALMD), a biomedical technology company, today...
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


